-
公开(公告)号：US20240182482A1
公开(公告)日：2024-06-06
申请号：US18281862
申请日：2022-04-28
发明人： Yuli XIE , Houxing FAN , Lihui QIAN
IPC分类号： C07D487/06 , A61K31/519 , C07D519/00
CPC分类号： C07D487/06 , A61K31/519 , C07D519/00
摘要： Disclosed in the present invention are a fused cyclic compound as a Wee-1 inhibitor, a preparation method therefor and use thereof. Specifically, the present invention relates to a compound of general formula (1), a preparation method therefor, and use of the compound of general formula (1) or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a Wee-1 inhibitor in the preparation of an anti-tumor drug.
-
公开(公告)号：US20200069609A1
公开(公告)日：2020-03-05
申请号：US16614481
申请日：2018-05-18
发明人： Cheng LUO , Zhiyi YAO , Yuli XIE , Wei WAN , Liyan YUE , Yuanyuan ZHANG , Hualiang JIANG , Kaixian CHEN
IPC分类号： A61K31/122 , C07K1/107 , C07K14/47 , C07K19/00
摘要： The present invention provides a method (I) for modifying a mammalian ATG8 homologue by a covalent bond, comprising: providing a compound SM-LG including a moiety SM- having a function of modulating a mammalian ATG8 homologue and a leaving moiety -LG; the compound SM-LG reacts with a mammalian ATG8 homologue to produce a covalent complex of the mammalian ATG8 homologue. The invention also provides a covalent complex of the mammalian ATG8 homologue obtained by the method and uses of the same.
-
3.发明公开公开(公告)号：US20240287075A1
公开(公告)日：2024-08-29
申请号：US18288803
申请日：2022-07-05
发明人： Yuli XIE , Houxing FAN , Lihui QIAN
IPC分类号： C07D487/04 , A61K31/4196 , A61K31/437 , A61K31/444 , A61K31/55 , A61P35/00 , C07D471/04
CPC分类号： C07D487/04 , A61K31/4196 , A61K31/437 , A61K31/444 , A61K31/55 , A61P35/00 , C07D471/04
摘要： The present invention relates to a 1,2,4-triazolone derivative as a DHODH inhibitor, a preparation method therefor and use thereof. Specifically, the present invention relates to a compound of general formula (1), a preparation method therefor, and use of the compound of general formula (1) and an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a DHODH inhibitor in the treatment of DHODH-related diseases.
-
公开(公告)号：US20230128824A1
公开(公告)日：2023-04-27
申请号：US17799060
申请日：2021-03-23
发明人： Yuli XIE , Houxing FAN , Gang CAO , Lihui QIAN
IPC分类号： C07D471/10 , C07D519/00 , A61P35/00
摘要： The present invention relates to a compound of general formula (1) and a preparation method therefor, and use of the compound of formula (1) and isomers, crystalline forms and pharmaceutically acceptable salts thereof as an irreversible inhibitor for a K-Ras G12C mutant protein in preparing a medicament for resisting Ras-related diseases such as tumors.
-
公开(公告)号：US20210053945A1
公开(公告)日：2021-02-25
申请号：US17071949
申请日：2020-10-15
发明人： Houxing FAN , Yuli XIE
IPC分类号： C07D403/12 , C07D491/107 , C07D471/10 , C07D487/10 , C07D471/08 , C07D413/12 , C07D471/04 , C07D487/04 , C07D403/14 , A61P35/04
摘要： The invention relates to a series of novel compounds containing acryloyl group. In particular, the invention relates to acryloyl group-containing compounds shown in formula (1) and the preparation method thereof, and application of the compounds shown in formula (1) and pharmaceutically acceptable salts thereof in preparation of medicaments for treating, regulating and/or preventing diseases related to physiological conditions related to CRM1 protein.
-
公开(公告)号：US20240317741A1
公开(公告)日：2024-09-26
申请号：US18578384
申请日：2022-08-11
发明人： Yuli XIE , Wenzhong LIU , Lihui QIAN
IPC分类号： C07D471/04 , A61K31/5377 , A61K31/675 , A61P35/00 , C07F9/6558
CPC分类号： C07D471/04 , A61K31/5377 , A61K31/675 , A61P35/00 , C07F9/65583
摘要： Disclosed are a naphthyridine derivative as an ATR inhibitor, a method for preparing same, and use thereof. Specifically, the present invention relates to a naphthyridine compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) and an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as an ATR inhibitor. The compound and the isomer, the crystalline form, the pharmaceutically acceptable salt, the hydrate or the solvate thereof of the present invention can be used for preparing a medicament for treating or preventing a related disease mediated by ATR protein kinase.
-
公开(公告)号：US20240287067A1
公开(公告)日：2024-08-29
申请号：US18633460
申请日：2024-04-11
发明人： Yuli XIE , Yingming WU , Lihui QIAN
IPC分类号： C07D471/04 , A61K31/437
CPC分类号： C07D471/04 , A61K31/437
摘要： Disclosed in the present invention are compounds as MYT1 inhibitors. Particularly, the present invention relates to compounds represented by general formula (1) and a preparation method therefor, as well as the use of the compounds of general formula (1), and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof as MYT1 inhibitors. The compounds of the present invention as well as the isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof can be used for preparing drugs for treating or preventing diseases related to MYT1 protein.
-
公开(公告)号：US20240182447A1
公开(公告)日：2024-06-06
申请号：US18277987
申请日：2022-02-15
发明人： Yuli XIE , Yingming WU , Houxing FAN , Lihui QIAN
IPC分类号： C07D401/14 , A61P35/00 , C07D471/04 , C07D491/044 , C07D495/04 , C07F9/6558 , C07F9/6568
CPC分类号： C07D401/14 , A61P35/00 , C07D471/04 , C07D491/044 , C07D495/04 , C07F9/65586 , C07F9/6568
摘要： The present invention discloses a fused cyclic compound as a Wee-1 inhibitor. Specifically, the present invention relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a Wee-1 inhibitor in the preparation of an anti-tumor drug.
-
公开(公告)号：US20230174550A1
公开(公告)日：2023-06-08
申请号：US17922345
申请日：2021-06-28
发明人： Yuli XIE , Houxing FAN , Lihui QIAN
IPC分类号： C07D498/04 , A61P35/00 , C07D519/00 , C07D487/04
CPC分类号： C07D498/04 , A61P35/00 , C07D519/00 , C07D487/04
摘要： The present invention relates to a compound of general formula (1a) or general formula (1b) and a method for preparing the same, and use of the compound of general formula (1a) or general formula (1b) and an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as an irreversible inhibitor for an IDH mutant in preparing a medicament for resisting a diseases such as a tumor related to an IDH mutant protein.
-
公开(公告)号：US20210198261A1
公开(公告)日：2021-07-01
申请号：US17200854
申请日：2021-03-14
发明人： Yuli XIE , Houxing FAN
IPC分类号： C07D471/14 , C07D401/14
摘要： The invention relates to a type of novel pyridine compound and a preparation method and application thereof. Specifically, the invention relates to a compound of formula (1) and a preparation method thereof, and an application of the compound of formula (1) and pharmaceutically acceptable salts thereof as aurora kinase inhibitors in preparation of anti-tumor drugs.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.019 秒)
